A phase II open-label study of the safety and efficacy of atiprimod treatment for patients with low to intermediate grade neuroendocrine carcinoma
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Atiprimod (Primary)
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 30 Aug 2011 Actual end date of the extension trial (NCT00663429) is Mar 2010 as reported by ClinicalTrials.gov.
- 30 Aug 2011 Actual end date of the extension trial (NCT00663429) is Mar 2010 as reported by ClinicalTrials.gov.
- 30 Aug 2011 Actual initiation date of the extension trial (NCT00663429) is Nov 2007 as reported by ClinicalTrials.gov.